MARATTO

article · RSC Advances

Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens

202233 citationsOpen accessBadr University in Cairo

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

As promising antimicrobials against MDR pathogens, two novel series of isatin thiazolyl-pyrazoline conjugates were developed. Compounds 9f and 10h were the most effective against the tested MDR strains.

Research topics

  • Synthesis and biological activity
  • Cancer therapeutics and mechanisms
  • Antimicrobial Peptides and Activities

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1039/d2ra04385h

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.